Novartis Ends Mid-Stage Fabhalta Trial in Lupus Nephritis Citing Strategic Considerations
The drug remains approved for other kidney diseases.
/ 26 items
#NVS↓
Novartis’ Rhapsido becomes first FDA-approved treatment for symptomatic dermographism
Rhapsido is now FDA-approved for symptomatic dermographism and chronic spontaneous urticaria when H1 antihistamines are not enough.
Novartis licenses Abogen’s mRNA autoimmune drug in deal worth up to $7.8 billion
Novartis will pay $575 million upfront for worldwide rights to Abogen's mRNA T-cell engager, plus up to $7.2 billion in milestones.
Roche and Ionis Report Phase 3 Proteinuria Win for Sefaxersen in IgA Nephropathy
Roche-Ionis sefaxersen beat placebo on proteinuria at week 37 in IgAN Phase 3. Monthly shot enters crowded market vs Novartis Fabhalta.
BoomRay Signs Exclusive $900 Million Radioligand Deal With Novartis
Chinese biotech BoomRay licenses a preclinical radioligand therapy to Novartis in a deal worth up to $900 million plus royalties.
Amgen Drug Succeeds in Late-Stage Sjögren’s Disease Trial
Amgen’s dazodalibep met its Phase 3 goal in moderate-to-severe Sjögren’s disease, showing lasting improvement in systemic activity. A second trial is due later in 2026.